Celltrion files suits against Genentech for Herceptin, Rituxan patents

 
(Ref: The Korea Herald)
  • Celltrion filed two lawsuits challenging the validity of Roche's patents for the breast cancer drug Herceptin and the lymphoma treatment Rituxan as the Korean company seeks to launch its biosimilar versions in the US, reported The Korea Herald.

  • The lawsuits filed in California district court are seeking a declaratory judgment that 38 patents relating to Herceptin and 37 patents relating to Rituxan are non-infringing and invalid.

  • The move comes as Celltrion awaits FDA approval to market its two biosimilar products Herzuma and Truxima, which reference Herceptin and Rituxan, respectively.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>